Radiation modulation of microRNA in prostate cancer cell lines

Sajni Josson1, Shian-Ying Sung, Kaiqin Lao

  • 1Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA. sjosson@emory.edu

The Prostate
|August 1, 2008
PubMed
Abstract

Insights

MicroRNAs (miRNA) regulate genes and impact cellular stress responses. This study found that miR-521 sensitizes prostate cancer cells to radiation by downregulating the DNA repair protein CSA, suggesting miR-521 as a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression.
  • miRNAs play a critical role in cellular responses to stress.
  • Prostate cancer cells exhibit altered miRNA profiles under stress.

Purpose of the Study:

  • To investigate the role of specific microRNAs (miRNAs) in prostate cancer cell response to radiation.
  • To identify miRNAs that modulate radio-sensitivity in prostate cancer.
  • To elucidate the molecular mechanisms underlying miRNA-mediated radio-sensitivity.

Main Methods:

  • Global miRNA screening using multiplexed quantitative real-time PCR in prostate cancer cells.
  • Transient overexpression and ectopic inhibition of specific miRNAs (miR-521).
  • Measurement of target protein expression (Cockayne syndrome protein A - CSA) via quantitative methods.

Main Results:

  • Radiation treatment significantly altered miRNA expression in prostate cancer cells, notably miR-521 and miR-34c.
  • Overexpression of miR-521 sensitized cells to radiation, while inhibition led to resistance.
  • miR-521 inversely correlated with CSA protein levels, a DNA repair protein; radiation downregulated miR-521 and upregulated CSA.

Conclusions:

  • miR-521 modulates the expression of the DNA repair protein CSA.
  • miR-521 significantly influences the radio-sensitivity of prostate cancer cell lines.
  • miR-521 represents a potential therapeutic target for enhancing radiation treatment efficacy in prostate cancer.